(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
4 days till quarter result
(bmo 2024-05-09)
Expected move: +/- 9.75%
Live Chart Being Loaded With Signals
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders...
Stats | |
---|---|
今日成交量 | 131 554 |
平均成交量 | 123 283 |
市值 | 607.69M |
EPS | $0 ( 2024-03-07 ) |
下一个收益日期 | ( $-0.220 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -17.18 |
ATR14 | $0.0550 (0.47%) |
音量 相关性
GH Research PLC 相关性 - 货币/商品
GH Research PLC 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $-315 000 (0.00 %) |
EPS: | $-0.680 |
FY | 2023 |
营收: | $0 |
毛利润: | $-315 000 (0.00 %) |
EPS: | $-0.680 |
FY | 2022 |
营收: | $0 |
毛利润: | $-47 000.00 (0.00 %) |
EPS: | $-0.140 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-0.211 |
Financial Reports:
No articles found.
GH Research PLC
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。